Drutovic David, Chripkova Martina, Pilatova Martina, Kruzliak Peter, Perjesi Pal, Sarissky Marek, Lupi Monica, Damia Giovanna, Broggini Massimo, Mojzis Jan
Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Košice, Slovak Republic.
Tumour Biol. 2014 Oct;35(10):9967-75. doi: 10.1007/s13277-014-2289-y. Epub 2014 Jul 10.
Colorectal cancer is the third most common cancer in the world, with 1.2 million new cancer cases annually. Chalcones are secondary metabolite precursors of flavonoids that exhibit diverse biological activities, including antioxidant and antitumor activities. The aim of this study was to investigate the antiproliferative effect of new synthetic chalcone derivatives on HCT116 cells. (E)-2-(2',4'-dimethoxybenzylidene)-1-tetralone (Q705) was found to be the most active (IC50 = 3.44 ± 0.25 μM). Based on these results, this compound was chosen for further analysis of its biochemical and molecular mechanisms. Our results showed that Q705 inhibited the growth and clonogenicity of HCT116 cells. The results of a flow cytometric analyses suggested that this compound caused a significant cell cycle arrest in G2/M phase and increased the proportion of cells in the subG0/G1 phase, marker of apoptosis. Q705-induced apoptosis was confirmed by TdT-mediated dUTP nick end labelling (TUNEL) assay. Treatment of HCT116 cells with this chalcone significantly increased the caspase-3,-7 activity and resulted in cleavage of poly-ADP-ribose polymerase (PARP). Changes in the nuclear morphology such as chromatin condensation were also observed. These effects were associated with a decreased expression of bcl-xL and increased overall ratio of bax/bcl-xL mRNA levels. Immunofluorescence and qRT-PCR analysis revealed that Q705 induced H2AX histone modifications characteristic of DNA damage, disruption of microtubule organization and downregulation of tubulins. In summary, these results suggest that the cyclic chalcone analogue Q705 has potential as a new compound for colorectal cancer therapy.
结直肠癌是全球第三大常见癌症,每年有120万新增癌症病例。查耳酮是黄酮类化合物的次生代谢产物前体,具有多种生物活性,包括抗氧化和抗肿瘤活性。本研究的目的是研究新型合成查耳酮衍生物对HCT116细胞的抗增殖作用。发现(E)-2-(2',4'-二甲氧基亚苄基)-1-四氢萘酮(Q705)活性最强(IC50 = 3.44±0.25μM)。基于这些结果,选择该化合物进一步分析其生化和分子机制。我们的结果表明,Q705抑制HCT116细胞的生长和克隆形成能力。流式细胞术分析结果表明,该化合物导致细胞周期在G2/M期显著停滞,并增加了亚G0/G1期细胞的比例,这是细胞凋亡的标志。TdT介导的dUTP缺口末端标记(TUNEL)试验证实了Q705诱导的细胞凋亡。用这种查耳酮处理HCT116细胞显著增加了caspase-3、-7的活性,并导致聚ADP核糖聚合酶(PARP)的裂解。还观察到核形态的变化,如染色质浓缩。这些效应与bcl-xL表达降低和bax/bcl-xL mRNA水平的总体比值增加有关。免疫荧光和qRT-PCR分析显示,Q705诱导了具有DNA损伤特征的H2AX组蛋白修饰、微管组织破坏和微管蛋白下调。总之,这些结果表明,环状查耳酮类似物Q705有潜力作为一种治疗结直肠癌的新化合物。